Aquestive Therapeutics, Inc.
AQST
$4.06
$0.041.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -22.61% | -26.32% | -24.38% | 5.29% | 13.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.61% | -26.32% | -24.38% | 5.29% | 13.80% |
| Cost of Revenue | 3.82% | -4.39% | -6.64% | -16.35% | -14.20% |
| Gross Profit | -34.52% | -36.00% | -32.54% | 19.58% | 33.40% |
| SG&A Expenses | 59.13% | 44.18% | 53.70% | 67.40% | 58.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.87% | 23.98% | 31.52% | 34.46% | 34.48% |
| Operating Income | -130.90% | -164.37% | -246.29% | -111.67% | -103.75% |
| Income Before Tax | -89.77% | -96.61% | -152.57% | -90.22% | -479.03% |
| Income Tax Expenses | -- | -113.86% | 64.10% | -105.71% | -105.71% |
| Earnings from Continuing Operations | -89.83% | -96.00% | -152.89% | -88.55% | -460.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -89.83% | -96.00% | -152.89% | -88.55% | -460.83% |
| EBIT | -130.90% | -164.37% | -246.29% | -111.67% | -103.75% |
| EBITDA | -134.69% | -175.49% | -270.86% | -122.56% | -118.72% |
| EPS Basic | -50.11% | -55.71% | -93.41% | -36.54% | -378.65% |
| Normalized Basic EPS | -49.09% | -52.98% | -88.88% | -44.07% | -122.00% |
| EPS Diluted | -50.11% | -55.71% | -93.41% | -36.54% | -261.66% |
| Normalized Diluted EPS | -49.09% | -52.98% | -88.88% | -44.07% | -122.31% |
| Average Basic Shares Outstanding | 23.23% | 22.86% | 27.23% | 40.27% | 41.63% |
| Average Diluted Shares Outstanding | 23.23% | 22.86% | 27.23% | 40.27% | 31.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |